Trial · NCT05820763
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
NCT05820763, Phase 2, Withdrawn, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant. Trials, record NCT05820763. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05820763
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
- NCT number
- NCT05820763
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Multiple Myeloma, Myeloma-Associated Amyloidosis
- Interventions
- Selinexor, Lenalidomide, Dexamethasone
- First posted
- 2023-04-20
- Last updated
- 2024-07-10
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Minimal Residual Disease (MRD) negativity | At the end of consolidation treatment (at the end of 4 cycles (each cycle is 28 days) | Defined by rate of MRD negativity using clonoSEQ MRD® assay at a sensitivity of 10\^-5. MRD negativity is defined as 0 residual clonal cells in a bone marrow biopsy sample. |
| Primary | Rate of Minimal Residual Disease (MRD) negativity | 12 months from study treatment initiation | Defined by rate of MRD negativity using clonoSEQ MRD® assay at a sensitivity of 10\^-5. MRD negativity is defined as 0 residual clonal cells in a bone marrow biopsy sample. |
| Secondary | Rate of partial response or better | 12 months from study treatment initiation | Defined as the rate of patients achieving a partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR), as defined by standard IMWG response criteria. |
| Secondary | Progression-free survival (PFS) | 12 months from study treatment initiation | PFS will be defined as time from AHCT to progression, relapse, or death, whichever occurs first, and those event-free survivors will be censored at withdrawal or study closeout |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05820763
GET https://conductscience.org/api/trials/v1/NCT05820763/registered